Minakem-flap
Minakem-flap

Find FDA Investigational New Drug (IND) Submissions for Neurology

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PMN310

            Therapeutic Area: Neurology Product Name: PMN310

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Fenway Sports Group

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 22, 2021

            Details:

            ProMIS plans to accelerate progress toward a number of top priorities, including; Advancing the PMN310 monoclonal antibody into clinical testing; Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2021

            Details:

            28% and 32% significant reductions in first and total strokes, respectively, Showed with VASCEPA compared to placebo and reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated CV risk.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): YTX-7739

            Therapeutic Area: Neurology Product Name: YTX-7739

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 09, 2021

            Details:

            YTX-7739 prevented motor function deficits in the diseased mice after four months of YTX-7739 oral dosing compared to placebo-treated mice. YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amniotic fluid derived stem cells

            Therapeutic Area: Neurology Product Name: ImmCelz

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2021

            Details:

            Creative Medical Technology Holdings reported that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz IND for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.